EN
DE
Home
About us
Biofronteras Expertise
Management and supervisory board
Product Pipeline
Clinical trials
Products
Product Portfolio
Investors & Media
Key stock information
Financial reports
Financial announcements
Shareholder structure
Corporate calendar
Corporate governance
Annual general meeting
Presentations & contact
Career
Careers
Contact
Biofrontera
Investors & Media
Financial announcements
Latest News Releases
04/30/2024 10:15
PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FINANCIAL YEAR 2023
04/04/2024 19:45
PTA-Adhoc: Biofrontera AG: Biofrontera AG resolves capital increase from authorized capital
02/20/2024 14:15
PTA-News: Biofrontera AG: Biofrontera transfers clinical research to the U.S.
02/20/2024 13:45
PTA-Adhoc: Biofrontera AG: Biofrontera AG announces revised strategy
02/19/2024 11:45
PTA-News: Biofrontera AG: Biofrontera and GME enter into a cooperation to promote the MultiLite® daylight lamp for PDT treatment
02/15/2024 21:20
PTA-Adhoc: Biofrontera AG: Biofrontera AG plans capital reduction and considers subsequent capital increase from authorized capital
02/05/2024 10:15
PTA-News: Biofrontera AG: Ameluz® obtains approval extension for use with artificial daylight in the EU and the UK
01/24/2024 11:20
PTA-News: Biofrontera AG: EMA approves an optimized formulation of Ameluz®
01/08/2024 15:38
PTA-News: Biofrontera AG: EMA recommends Ameluz® label extension for actinic keratosis treatment with artificial daylight
11/28/2023 09:30
PTA-News: Biofrontera AG: Biofrontera Reports Business Performance in the Third Quarter and First Nine Months of 2023
Financial announcements
Material News
Current & Archive (Related Party Transactions incl.)
Corporate News
Current & Archive
Voting Rights
Notifications
Current & Archive
Directors' Dealings
Current & Archive